Financial Advocates Investment Management Makes New Investment in argenx SE (NASDAQ:ARGX)

Financial Advocates Investment Management purchased a new stake in shares of argenx SE (NASDAQ:ARGX) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 386 shares of the company’s stock, valued at approximately $237,000.

Other hedge funds also recently bought and sold shares of the company. Cromwell Holdings LLC boosted its holdings in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after purchasing an additional 66 shares during the period. GAMMA Investing LLC raised its position in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares in the last quarter. Blue Trust Inc. boosted its stake in argenx by 413.9% during the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after buying an additional 298 shares during the period. Keudell Morrison Wealth Management purchased a new position in argenx during the third quarter worth about $207,000. Finally, SG Americas Securities LLC increased its stake in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after acquiring an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on ARGX. JMP Securities boosted their price target on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective on the stock in a research report on Tuesday, November 12th. Oppenheimer restated an “outperform” rating and issued a $675.00 target price (up previously from $646.00) on shares of argenx in a research report on Thursday, November 21st. Truist Financial restated a “buy” rating and issued a $700.00 price objective (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Wells Fargo & Company increased their target price on shares of argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Stock Down 1.7 %

Shares of argenx stock opened at $646.64 on Monday. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The company’s 50 day moving average is $637.11 and its 200 day moving average is $577.73. The company has a market cap of $39.29 billion, a price-to-earnings ratio of -734.82 and a beta of 0.58.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.